Purpose The primary objective of this study was to evaluate 1- and 2-year survival rates and durable remissions in pretreated patients with advanced (unresectable or metastatic) malignant melanoma treated with ipilimumab in a South African expanded-access program (SA-EAP).

Patients and Methods This multicenter, retrospective study obtained data from pretreated patients with advanced malignant melanoma who were eligible for the ipilimumab SA-EAP. Ipilimumab was administered at a dose of 3 mg/kg intravenously every 3 weeks for four cycles to adults with advanced melanoma for whom at least one line of treatment for metastatic disease had failed. Data from the medical records of 108 patients treated within the SA-EAP were collected and statistically analyzed to determine overall (OS) and progression-free survival (PFS) at 1 and 2 years.

Results In the population of 108 patients, a median OS of 8.98 months (95% CI, 7.47 to 10.79 months) was observed. One-year OS was 36% (95% CI, 26% to 45%), and 2-year survival was observed as 20% (95% CI, 12% to 27%). The median survival without progression (ie, PFS) was 3.44 months (95% CI, 2.98 to 4.16 months), and 1- and 2-year PFS were 22% (95% CI, 14% to 29%) and 14% (95% CI, 8% to 21%), respectively. The longest recorded survival was 3.4 years. No independent prognostic variables were identified to predict for OS by multivariate Cox proportional hazards model.

Conclusion In this multicenter South African setting, ipilimumab at a dose of 3 mg/kg was an effective treatment with long-term OS in a subset of patients with pretreated advanced malignant melanoma.

INTRODUCTION
In South Africa, melanoma is the eighth most common documented cancer in men, with a lifetime risk of one in every 186 men; in women, melanoma is the sixth most common cancer, with a lifetime risk of one in every 297 women. According to the South African National Cancer Registry (2005), whites are at higher risk; melanoma is the fifth most common cancer among white men and remains the sixth most common cancer in white women. Although evidence indicates that mortality rates are declining or stabilizing for certain populations or countries, partially because of heightened awareness and detection of disease at an earlier stage, mortality for advanced (unresectable or metastatic) melanoma remains high. Survival for stage IV disease, in particular, remains poor, with median survival times across studies ranging from 6 to approximately 12 months. Treatment of metastatic melanoma continues to represent a considerable unmet medical need on the basis of the rising worldwide incidence of the disease and the unsatisfactory efficacy and significant toxicities of currently available drugs.

Ipilimumab (YERVOY; Bristol-Myers Squibb, New York, NY) is a fully humanized monoclonal antibody directed against cytotoxic T-cell lymphocyte antigen-4 and the first treatment to demonstrate a survival benefit in advanced malignant melanoma. Efficacy data are largely based on results from two phase III clinical trials. The MDX010-20 study compared ipilimumab 3 mg/kg with an interventional vaccine, with increased median overall survival (OS) in the ipilimumab arm of 3.7 months (hazard ratio, 0.66; P = .003). The other study compared ipilimumab 10 mg/kg plus dacarbazine with dacarbazine alone, with higher 1-year OS in
the ipilimumab arm (47.3% v 36.3%). A meta-analysis of 15 trials reported a median OS of 18.8 months with ipilimumab monotherapy (at 3 mg/kg) compared with 12.3 months with single-agent chemotherapy. Because of the limited data reported on the use of ipilimumab in metastatic malignant melanoma in developing countries, our retrospective study was undertaken to evaluate the long-term outcomes of ipilimumab, administered within a South African expanded access program (SA-EAP) in pretreated patients with this disease.

**PATIENTS AND METHODS**

**Patient Population**

Patients were enrolled in the SA-EAP according to the following criteria: histologically confirmed stage III (unresectable) or stage IV (metastatic) cutaneous, ocular or mucosal melanoma, or asymptomatic brain metastases resulting from melanoma; failure of or intolerance to at least one prior systemic treatment; age ≥ 18 years; and Eastern Cooperative Oncology Group performance status of 2 or less. Patients were excluded from the study on the basis of contraindication to ipilimumab therapy (eg, known autoimmune disease, HIV, hepatitis B or C); presence of symptomatic brain metastases; receipt of other concurrent systemic anticancer treatments for melanoma; or presence of another active concurrent malignant disease, with the exception of adequately treated basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the cervix.

**Study Design**

In this multicenter retrospective study, data were extracted from patients' medical records to evaluate the outcomes of ipilimumab treatment. Institutional ethics approval was obtained from the Human Sciences Research Council of South Africa.

**Data Collection and Statistical Analysis**

The participating practices and academic institutions collected and recorded the required data on patient case report forms, which were returned to the study facilitator. The collected data were electronically captured on an Excel-based capturing tool (Microsoft, Redmond, WA) for analysis and analyzed using RStudio software (version 3.2.3; RStudio, Boston, MA).

Data from different points in time throughout a patient's medical history were reviewed. These data included four aspects of treatment history: demographic features, disease characteristics, initial treatment at the time of enrollment in the SA-EAP, and courses of treatment. The data reported on patient- and disease-related factors, including: demographic information, melanoma...

---

**Table 1.** Baseline Patient Demographic and Clinical Characteristics (N = 108)

| Characteristic                          | No. | % |
|----------------------------------------|-----|---|
| **Sex**                                |     |   |
| Male                                   | 73  | 68|
| Female                                 | 35  | 32|
| **Age, years**                         |     |   |
| Median                                 | 59  |   |
| Range                                  | 27-86|   |
| **Race**                               |     |   |
| Black                                  | 2   | 2 |
| Indian                                 | 2   | 2 |
| White                                  | 93  | 86|
| Mixed                                  | 1   | 1 |
| Not reported                           | 10  | 9 |
| **Time since diagnosis, months**       |     |   |
| (reported for n = 100 patients)        |     |   |
| Median                                 | 8   |   |
| Range                                  | 0-140|   |
| **Primary location of melanoma**       |     |   |
| Cutaneous                              | 84  | 78|
| Uveal                                  | 3   | 3 |
| Mucosal                                | 12  | 11|
| Metastatic (unknown primary)           | 9   | 8 |
| **Presence of brain metastases**        |     |   |
| Yes                                    | 19  | 18|
| No                                     | 89  | 82|
| **ECOG PS**                            |     |   |
| 0                                      | 36  | 34|
| 1                                      | 63  | 58|
| 2                                      | 7   | 6 |
| Not recorded                           | 2   | 2 |
| **LDH**                                |     |   |
| ULN                                    | 44  | 41|
| ULN > 1 to < 2                         | 9   | 8 |
| ULN > 2                                | 6   | 6 |
| Not recorded                           | 49  | 45|
| **No. of prior therapies for metastatic disease** | | |
| Median                                 | 1   |   |
| Range                                  | 1-5 |   |

**Abbreviations:** ECOG PS, Eastern Cooperative Oncology Group performance status; LDH, lactate dehydrogenase; ULN, upper limit of normal.

*Time from advanced melanoma diagnosis to first ipilimumab dose.*
Fig 1. Kaplan-Meier plot of overall survival (OS).
in the South African expanded-access program in (A) all patients, (B) patients who achieved complete response, (C) and patients without disease progression. Dashed lines indicate 95% CIs.

Table 3. Tumor Response for Mucosal and Uveal Melanomas and Metastatic Melanomas of Unknown Primary

| Response | Mucosal (%) | Metastatic Unknown (%) | Uveal (%) |
|----------|-------------|------------------------|-----------|
| PD       | 100         | 33                     | 100       |
| PR       | 0           | 50                     | 0         |
| SD       | 0           | 17                     | 0         |

Abbreviations: PD, progressive disease; PR, partial response; SD, stable disease.
Efficacy

The median OS (n = 108) was 8.98 months (95% CI, 7.47 to 10.79 months), and the 1-year survival rate was 36% (95% CI, 26% to 45%). The 2-year survival rate was 20% (95% CI, 12% to 27%). The median PFS (n = 108) was 3.44 months (95% CI, 2.98 to 4.16 months). The 1-year PFS rate was 22% (95% CI, 14% to 29%). The 2-year PFS rate was 14% (95% CI, 8% to 21%). At a median follow-up of 24 months, the median survival of patients who attained a CR, PR, or SD was not reached (Figs 1A to 1C).

Cox multivariate analysis for OS and PFS of various patient characteristics, using stepwise backward elimination, failed to demonstrate any significant variable. The relationships between absolute lymphocyte count and absolute eosinophil count and both OS and PFS were also examined. Although there was a trend toward increased OS and PFS with high absolute lymphocyte and eosinophil counts, significance was not demonstrated (P > .05).

The median time to progression (n = 108) was 3.44 months (95% CI, 2.98 to 4.16 months). Seventy-three percent of patients had experienced PD by 10 months (95% CI, 65% to 82%), and 90% (95% CI, 84% to 96%) had experienced PD by 40 months. Analysis of best overall response rates (n = 62) showed that the DCR was 53% (95% CI, 41% to 66%). Best overall response rates are listed in Table 2. According to the timeframes and retrospectively captured data, the median time to best response for patients whose best response was PR was 12 weeks; for patients achieving a CR, it was 24 weeks. Individual best overall response rates for patients with mucosal melanoma, uveal melanoma, or metastatic melanoma of unknown primary site are listed in Table 3.

AEs

Eleven severe AEs (grades 3 and 4) were reported; a majority of these were GI events. There were no reported deaths resulting from treatment-induced toxicities. Because these data were collected retrospectively, it is possible that toxicities were under-reported, particularly for grades 1 and 2. Additionally, and in view of the nature of the study, information on date of resolution and potential sequelae was not captured. AEs are summarized in Table 4.

DISCUSSION

This retrospective analysis of the SA-EAP in a population of 108 patients with advanced malignant melanoma showed that patients treated with ipilimumab obtained a median OS of 8.98 months (95% CI, 7.47 to 10.79 months) and 1-year OS of 36% (95% CI, 26% to 45%). These results are comparable to the outcomes reported in the prospective phase III pivotal trial of ipilimumab at a dose of 3 mg/kg in pretreated patients with melanoma.8 It must be emphasized that before registration of ipilimumab, there was no evidence-based second-line treatment approved

### Table 4. AEs Reported During the Study

| AE          | Grade 1 | Grade 2 | Grade 3 | Grade 4 |
|-------------|---------|---------|---------|---------|
| Cutaneous   | 8 (7)   | 3 (3)   |         |         |
| GI          | 6 (5)   | 10 (8)  | 7 (6)   | 1 (1)   |
| Hepatic     | 2 (2)   |         |         |         |
| Endocrine   | 2 (2)   |         |         |         |
| Blood related | 2 (2)  |         |         |         |
| Other       | 1 (1)   | 5 (4)   | 3 (3)   |         |

Abbreviation: AE, adverse event.

### Table 5. Results of Published Ipilimumab EAPs

| Author and Country | Dose (mg/kg) | No. of Patients | PFS (months) | OS (months) | 1-Year OS (%) | 2-Year OS (%) |
|--------------------|--------------|-----------------|--------------|-------------|---------------|---------------|
| Alexander15 (Australia) | 3            | 104             | 3            | 9.6         | 42.00         | 18.00         |
| Ascierto16 (Italy)   | 3            | 833             | 3.7          | 7.2         | NR            | NR            |
| Delyon17 (France)    | 3            | 73              | NR           | 9.1         | NR            | NR            |
| Wilgenhof18 (Belgium)| 3            | 50              | NR           | 7           | 45.20         | 28.80         |
| Ahmad19 (UK)         | 3            | 193             | 2.8          | 6.1         | 31.00         | 14.80         |
| Berrocal20 (Spain)   | 3            | 144             | NR           | 6.5         | 32.90         | NR            |
| Ku21 (USA)           | 10           | 53              | 2.6          | 7.2         | NR            | NR            |
| Altomonte21 (Italy)  | 10           | 74              | 7            | NR          | 17.00         | NR            |
| SA-EAP (South Africa)| 3            | 108             | 3.4          | 8.9         | 36.00         | 20.00         |

Abbreviations: EAP, expanded-access program; NR, not reported; OS, overall survival; PFS, progression-free survival; SA-EAP, South African expanded-access program.
or recommended by South African guidelines for these patients.

These outcomes exceed suggested benchmark survival targets (proposed from a meta-analysis of second-line melanoma treatments) of 6.5 months for median OS and 25% for 1-year OS. The real-world survival data from our study are similar to those reported in an ipilimumab access scheme using a 10-mg/kg dosing regimen (median OS, 7.2 to 9 months). The median PFS of 3.44 months (95% CI, 2.98 to 4.16 months) was also similar to those reported in an Australian study of a similar nature (3.0 months; 95% CI, 2.7 to 3.4 months) and in another published access scheme study (95% CI, 2.6 to 4.3 months).

Overall, our results are in line with those previously reported for EAPs with ipilimumab at doses of 3 and 10 mg/kg. Those results are summarized in Table 5.

One of the main weaknesses of our study relates to the retrospective nature of the investigation, the difficulties in controlling for selection bias, and the lack of a control group. A proportion of our patients did not complete ipilimumab treatment because of PD. Some of these patients may have had a short, predictable life expectancy with advanced disease. These patients are typically heavily overtreated and have limited therapeutic options and a lack of alternative options; they had an opportunity to receive ipilimumab within the framework of this EAP. As a result of the retrospective nature of the study, investigations of patients did not occur at predefined times; therefore, this may have resulted in over-reporting of DCR.

Some patients with melanoma treated with ipilimumab exhibit an initially increased size of tumor lesions, proved by biopsy as inflammatory cell infiltrates or necrosis, followed by a decreased tumor burden. These immune-related response patterns have been recognized in clinical trials of ipilimumab, including the documentation of new tumors associated with edema and infiltrates of immune cells and transient increases in baseline tumor lesions. Clinicians should be aware of the possible presence of pseudotumor progression, which could be regarded as PD. However, this effect occurs in less than 10% of patients and could not account for the early PD documented among the pretreated patients with metastatic melanoma accrued into our EAP.

Of the 108 patients, 43% discontinued ipilimumab permanently before having completed four doses. PD was cited as the most common reason for discontinuation of treatment. These results are comparable to those of other studies using a 3-mg/kg dose of ipilimumab (33% v 40.3%). Only 2% of patients discontinued treatment with ipilimumab because of severe immune-related AEs. This incidence is somewhat lower than percentages reported in the other studies (9.9% and 11.1%) however, the retrospective nature of our study might account for this observation.

Treatment with ipilimumab is associated with immune-related AEs. These immune-related AEs are related to the drug mechanism of action. In comparison with other published studies of ipilimumab, the overall incidence of grade 3 and 4 immune-related AEs (9.2%) in the SA-EAP was similar to that reported in the multicenter phase III
randomized controlled trial conducted by Hodi et al. These data suggest that the toxicity profile in the real-world setting is not different from that observed in clinical trial settings. Additionally, the use of ipilimumab at a dose of 3 mg/kg has a better safety profile than at 10 mg/kg, with similar outcomes. Some patients discontinued treatment early, decreasing the chance of developing immune-related AEs, which may account for the lower incidence of immune-related AEs.

Prior reports have indicated that an increase in absolute lymphocyte count and absolute eosinophil count occurring 3 weeks after treatment initiation may be associated with improved survival. Our data failed to show that. However, this once again may be a result of the retrospective nature of our study. Future studies should address this issue to further characterize this observation. Prospective studies examining lymphocyte subpopulations are required.

One of the most important aspects of treatment with checkpoint inhibitors is the improvement in survival and documentation of long-term durable remissions in some patients (Figs 2A and 2B). Future research should focus on improving the number of patients who will experience durable remissions and should include combination with other checkpoint inhibitors, gene therapy, vaccine therapy, and other immunostimulatory approaches.

In conclusion, our study of ipilimumab in the South African setting found that the efficacy and tolerability of ipilimumab at 3 mg/kg for the treatment of unresectable metastatic melanoma in pretreated patients align with data reported in several published studies with similar treatment doses and patient populations.

DOI: https://doi.org/10.1200/JGO.2016.006544
Published online on jgo.org on November 2, 2016.

**AUTHOR CONTRIBUTIONS**

**Conception and design:** Bernardo L. Rapoport, Daniel A. Vorobiof, Lydia M. Dreosti, Adam Nosworthy, Georgina McAdam, Helen Miller-Jansön, Margreet de Necker, Hennie Duvenhage

**Provision of study materials or patients:** Daniel A. Vorobiof, Adam Nosworthy

**Collection and assembly of data:** Bernardo L. Rapoport, Daniel A. Vorobiof, Lydia M. Dreosti, Adam Nosworthy, Georgina McAdam, Johan P. Jordaan, Helen Miller-Jansön, Margreet de Necker

**Data analysis and interpretation:** Bernardo L. Rapoport, Daniel A. Vorobiof, Lydia M. Dreosti, Georgina McAdam, Helen Miller-Jansön, Margreet de Necker, Janetta C. de Beer

**Manuscript writing:** All authors

**Final approval of manuscript:** All authors

**Accountable for all aspects of the work:** All authors

**AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST**

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO’s conflict of interest policy, please refer to www.asco.org/hwc or ascopubs.org/jco/site/ifc.

Bernardo L. Rapoport

**Honoraria:** Tesaro, Merck, Bristol-Myers Squibb

**Consulting or Advisory Role:** Tesaro, Merck, Bristol-Myers Squibb

**Speakers’ Bureau:** Tesaro, Merck, Bristol-Myers Squibb

**Research Funding:** Tesaro, Merck, Bristol-Myers Squibb

**Travel, Accommodations, Expenses:** Tesaro, Merck, Bristol-Myers Squibb

Daniel A. Vorobiof

**Consulting or Advisory Role:** Amgen, Roche, Bristol-Myers Squibb

Lydia M. Dreosti

**Honoraria:** Roche, Janssen Pharmaceuticals

**Consulting or Advisory Role:** Roche, Janssen Pharmaceuticals, Novartis

**Speakers’ Bureau:** Janssen Pharmaceuticals

**Travel, Accommodations, Expenses:** Roche, Janssen Pharmaceuticals, Merck Serono

Adam Nosworthy

**Speakers’ Bureau:** Key Oncologics

**Travel, Accommodations, Expenses:** Bristol-Myers Squibb, Janssen Oncology

Georgina McAdam

No relationship to disclose

Johan P. Jordaan

**Speakers’ Bureau:** Merck Serono

**Research Funding:** Roche, PAREXEL International, Ipsen, Quintiles, Novartis

**Travel, Accommodations, Expenses:** Roche

Helen Miller-Jansön

**Consulting or Advisory Role:** HEXOR (Inst)

**Research Funding:** HEXOR (Inst)

Margreet de Necker

**Consulting or Advisory Role:** HEXOR (Inst)

**Research Funding:** HEXOR (Inst)

Janetta C. de Beer

**Consulting or Advisory Role:** HEXOR (Inst)

**Research Funding:** HEXOR (Inst)

Hennie Duvenhage

**Employment:** Bristol-Myers Squibb

**Research Funding:** Bristol-Myers Squibb
ACKNOWLEDGMENT
We thank investigators L.R. Mare, Benoni Oncology Centre, Benoni; S.J. Fourie, Wilgers Oncology Centre, Pretoria; A. Verbeek, Gauteng Oncology, Olivedale Hospital, Randburg; D. Geldenhuys, Westrand Oncology Centre, Roodepoort; G.A. Landers, The Oncology Centre, Durban; G.B. McMichael, Westrand Oncology Centre, Roodepoort; H. Neethling, HN Oncology, Nelspruit; J. Malan, Langenhoven Drive Oncology Centre, Port Elizabeth; L. Jooste, Hopelands Cancer Centre, Durban; L. Heslop, Durban Oncology Centre, Durban; S. Bonnet, Bloemfontein Mediclinic, Bloemfontein; S. Cullis, Hopelans Cancer Centre, Pietermaritzburg; S. Rodrigues, Gauteng Oncology Netcare Clinton Hospital, Johannesburg; W.M. Szpak, Rainbow Oncology, Durban; W.R. Bezwoda, Netcare Rosebank Clinic, Johannesburg; and M.P. Stander, HEXOR, Midrand, South Africa.

Affiliations
Bernardo L. Rapoport, Medical Oncology Centre of Rosebank; Daniel A. Vorobiof, Sandton Oncology Center; Adam Nosworthy, Wits Oncology Donald Gordon Medical Center; Henkie Duvenhage, Bristol-Myers Squibb South Africa, Johannesburg; Lydia M. Dreosti, University of Pretoria, Pretoria; Georgina McAdam, Rondebosch Oncology Medical Center, Cape Town; Johan P. Jordaan, Westridge Oncology Center, Durban; and Helen Miller-Janssen, Margreet de Necker, and Janetta C. de Beer, HEXOR, Midrand, South Africa.

Support
Supported by Bristol-Myers Squibb South Africa, which supplied ipilimumab and provided statistical support.

Prior Presentation
Presented at the 40th European Society for Medical Oncology Congress, Vienna, Austria, September 25-29, 2015.

REFERENCES
1. The South African National Cancer Registry: Summary statistics of cancer diagnosed histologically in 2005. http://www.nioh.ac.za/assets/files/Cancer%20Tables%202005.pdf
2. de Vries E, Bray FI, Coebergh JW., et al: Changing epidemiology of malignant cutaneous melanoma in Europe 1953-1997: Rising trends in incidence and mortality but recent stabilizations in Western Europe and decreases in Scandinavia. Int J Cancer 107:119-126, 2003
3. Cayuela A, Rodríguez-Dominguez S, Lapetra-Peralta J, et al: Has mortality from malignant melanoma stopped rising in Spain? Analysis of trends between 1975 and 2001. Br J Dermatol 152:997-1000, 2005
4. Lasithiotakis KG, Leiter U, Gorkievicz R, et al: The incidence and mortality of cutaneous melanoma in Southern Germany: Trends by anatomic site and pathologic characteristics, 1976 to 2003. Cancer 107:1331-1339, 2006
5. Bosetti C, La Vecchia C, Naldi L, et al: Mortality from cutaneous malignant melanoma in Europe: Has the epidemic levelled off? Melanoma Res 14:301-309, 2004
6. Niezgoda A, Niezgoda P, Czajkowski R: Novel approaches to treatment of advanced melanoma: A review on targeted therapy and immunotherapy. BioMed Res Int 2015:851387, 2015
7. Serrone L, Zeuli M, Sega FM., et al: Dacarbazine-based chemotherapy for metastatic melanoma: Thirty-year experience overview. J Exp Clin Cancer Res 19:21-34, 2000
8. Hodi FS, O’Day SJ, McDermott DF, et al: Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711-723, 2010
9. Robert C, Thomas L, Bondarenko I, et al: Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 364:2517-2526, 2011
10. Dequen P, Lorigan P, Jansen JP, et al: Systematic review and network meta-analysis of overall survival comparing 3 mg/kg ipilimumab with alternative therapies in the management of pretreated patients with unresectable stage III or IV melanoma. Oncologist 17:1376-1385, 2012
11. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
12. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
13. Korn EL, Liu P-Y, Lee SJ, et al: Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J Clin Oncol 26:527-534, 2008
14. Ku KY, Yuan J, Page DB, et al: Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: Lymphocyte count after 2 doses correlates with survival. Cancer 116:1767-1775, 2010
15. Alexander M, Mellor JD, McArthur G, et al: Ipilimumab in pretreated patients with unresectable or metastatic cutaneous, uveal and mucosal melanoma. Med J Aust 201:49-53, 2014
16. Ascierto PA, Simeone E, Sileni VC, et al: Clinical experience with ipilimumab 3 mg/kg: Real-world efficacy and safety data from an expanded access programme cohort. J Transl Med 12:116, 2014
17. Delyon J, Mateus C, Lefevre D, et al: Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: An early increase in lymphocyte and eosinophil counts is associated with improved survival. Ann Oncol 24:1697-1703, 2013

18. Wilgenhof S, Du Four S, Vandenbroucke F, et al: Single-center experience with ipilimumab in an expanded access program for patients with pretreated advanced melanoma. J Immunother 36:215-222, 2013

19. Ahmad SS, Qian W, Ellis S, et al: Ipilimumab in the real world: The UK expanded access programme experience in previously treated advanced melanoma patients. Melanoma Res 25:432-442, 2015

20. Berrocal A, Arance A, Lopez Martin JA, et al: Ipilimumab for advanced melanoma: Experience from the Spanish expanded access program. Melanoma Res 24:577-583, 2014

21. Altomonte M, Di Giacomo A, Queirolo P, et al: Clinical experience with ipilimumab 10 mg/kg in patients with melanoma treated at Italian centres as part of a European expanded access programme. J Exp Clin Cancer Res 32:82, 2013

22. Chiou VL, Burotto M: Pseudoprogression and immune-related response in solid tumors. J Clin Oncol 33:3541-3543, 2015